Acylaminothiazole derivatives, preparation method thereof and use of same in therapeutics

Details for Australian Patent Application No. 2005209442 (hide)

Owner sanofi-aventis

Inventors Baltzer, Sylvie; Van Dorsselaer, Viviane

Agent Davies Collison Cave

Pub. Number AU-B-2005209442

PCT Pub. Number WO2005/073226

Priority 0408115 22.07.04 FR; 0400387 16.01.04 FR

Filing date 7 January 2005

Wipo publication date 11 August 2005

Acceptance publication date 31 March 2011

International Classifications

C07D 277/46 (2006.01) Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings

C07D 277/48 (2006.01) Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings

C07D 417/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

27 July 2006 PCT application entered the National Phase

  PCT publication WO2005/073226 Priority application(s): WO2005/073226

31 March 2011 Application Accepted

  Published as AU-B-2005209442

28 July 2011 Standard Patent Sealed

2 August 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005209446-1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same

2005209441-Derivatives of N-` (1,5-diphenyl-1H-pyrazol-3-yl) sulphonamide with CB1 receptor affinity